Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice

AIMS/INTRODUCTION: Dipeptidyl peptidase‐4 inhibitors are used for treatment of patients with type 2 diabetes. In addition to glycemic control, these agents showed beneficial effects on lipid metabolism in clinical trials. However, the mechanism underlying the lipid‐lowering effect of dipeptidyl pept...

Full description

Saved in:
Bibliographic Details
Published in:J Diabetes Investig
Main Authors: Yano, Wataru, Inoue, Noriyuki, Ito, Shiori, Itou, Takahiro, Yasumura, Misako, Yoshinaka, Yasunobu, Hagita, Sumihiko, Goto, Moritaka, Nakagawa, Takashi, Inoue, Keisuke, Tanabe, Sohei, Kaku, Kohei
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2016
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5334308/
https://ncbi.nlm.nih.gov/pubmed/27860391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12593
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items